# Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $573,379

## Abstract

PROJECT SUMMARY/ABSTRACT
Children with advanced neuroblastoma (NBL) have poor outcomes despite aggressive, multimodal therapy and
new therapeutic approaches are needed. Recent studies have demonstrated that targeted 131I-MIBG
radiopharmaceutical therapy combining modulators of somatic epigenetic programs (vorinostat) and GD2-
targeted immunotherapy (dinutuximab) show substantial therapeutic promise. Although 131I-MIBG is one of the
most effective therapies for advanced NBL, not all patients will respond to this therapy and predictive
biomarkers of treatment response and mechanisms of resistance have not been identified. Our preliminary
work in NBL show that minimally invasive liquid biopsy strategies for the detection of circulating tumor DNA
(ctDNA), circulating tumor cells (CTCs), and cell-free GD2 levels can be successfully employed in longitudinal
samples without reliance on surgical procedures in this vulnerable pediatric population. In this proposal, we will
apply these technologies to samples collected from a randomized, phase 2 trial designed to identify the optimal
agents for combination with 131I-MIBG in relapsed/refractory NBL (NANT 2021-02 [N21-02]) launching soon.
Patients are randomized to either (A) vorinostat + 131I-MIBG; (B) dinutuximab + 131I-MIBG; or (C) vorinostat +
dinutuximab + 131I-MIBG. Our overall hypothesis is that circulating biomarker levels will be associated with
treatment response for each combination being tested in this trial. We further hypothesize that selection for
mutations, changes in chromatin signatures, and downregulation of antigen expression will be associated with
disease progression. In Aim 1, we will profile serial plasma samples to detect and quantify ctDNA levels and
measure the association between ctDNA levels and response to therapy on each arm of N21-02. Furthermore,
we will identify mutations associated with the development of treatment resistance through deep sequencing of
ctDNA samples. In Aim 2, we will validate our existing chromatin accessibility and gene expression signatures
associated with vorinostat treatment in preclinical models and in vorinostat-treated patient samples. We will
then leverage serial liquid biopsy samples from patients enrolled on N21-02 treated with and without vorinostat
to detect induction of vorinostat signatures to determine whether these signatures are associated with
responses to vorinostat-containing therapies. Finally, in Aim 3, we will longitudinally measure soluble GD2
levels and surface expression levels on CTCs in samples collected from patients on dinutuximab-containing
treatment arms and compare GD2 levels to patients not receiving dinutuximab therapy. We will test the
association of soluble GD2 levels and response to GD2-directed therapy and determine whether changes in
GD2 expression on CTCs are associated with the development of disease progression on therapy. At the end
of this award, we expect to identify biomarkers of response and mechanisms of tre...

## Key facts

- **NIH application ID:** 10777970
- **Project number:** 1R01CA285681-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Brian Crompton
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $573,379
- **Award type:** 1
- **Project period:** 2024-04-01 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10777970

## Citation

> US National Institutes of Health, RePORTER application 10777970, Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma (1R01CA285681-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10777970. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*